Clinical Trials Browser

Phase 2 × INDUSTRY × Crizotinib × Clear all

NCT01945021 2021-02-21

Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

Phase 2 Completed

129 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT00932451 2017-01-13

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Phase 2 Completed

1,069 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT01500824 2013-02-25

A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung